PubMed Health⌕ Search

Biomedical subjects

G Richet

Publications and source records attributed to G Richet.

At least 19 recordsLinked to original sources
PubMed1991

From Bright's disease to modern nephrology: Pierre Rayer's innovative method of clinical investigation.

Pierre Rayer, in a day of purely descriptive medicine, devised a method for the scientific study of diseases affecting the kidney and urinary tract. He first assembled vivid illustrations of a wide range of disorders of the kidney found in specimens obtained at autopsy. The resulting Atlas won him widespread praise and is still often cited. His Treatise (Traité des Maladies des Reins et des Altérations de la Sécrétion Urinaire), in which he integrated data from pathological anatomy with urinary biology and clinical manifestations, was ahead of its time. Hence it was poorly understood and, like the work of many other innovators, was largely ignored. Nevertheless, his 2100 page Traité which begins with a description of his innovative and highly disciplined method of study, most unusual at this time, is by no means lacking in interest for today's nephrologists. Rayer's was a landmark contribution, affording, as it did, a comprehensive approach to the clinical problems of nephrology a century before the diseases themselves could be understood. Could a contemporary of Rayer tell that he was an inventor of scientific methodology before the proof of his rigorous demonstrations was carried out? That has been the achievement of clinical nephrology in the past forty years...one century later.

Glomerulonephritis↗
PubMed1990

[Evaluation of medical faculties in France].

A "comité national d'évaluation" founded in 1985 scrutinizes the french universities, autonomous but still partly run by the government. So far 17 medical faculties have been examined. Here are presented some remarks on the following points: the selection of the students and the end of the first year and the fate of those who failed; the reinforcement of science teaching for the students eager to go into research or academic medicine; the links binding teaching and research; the international relationships; the impulse of the evaluation on the Faculté.

Curriculum↗
PubMed1986

Characterization of monoclonal antibodies specific for human Tamm-Horsfall protein.

Fifteen monoclonal antibodies have been produced to human Tamm-Horsfall protein (THP), identifying at least seven distinct epitopes. The antibodies have been used to isolate from serum an immunoreactive protein which comigrates with urinary THP. In addition, the antibodies may prove useful to set up an immunoenzymoassay for urinary THP as well as for immunoaffinity purification.

Antibodies, Monoclonal↗
PubMed1986

Effects of tertatolol in hypertensive patients with chronic renal failure.

Chronic renal failure (CRF) is often associated with hypertension, as a cause or a consequence. We studied the changes in blood pressure (BP), heart rate (HR), renal function (as measured by creatinine clearance), and plasma renin activity (PRA) in 19 hypertensive patients with CRF before, during and after oral administration once a day for at least 30 days of 5 mg tertatolol, a new beta-blocker. All patients were free of any antihypertensive medication for at least 1 month before administration of tertatolol. The dose of tertatolol given in this study was the same as that commonly used in patients with normal renal function. From day 0 to day 30 of tertatolol, measurements in the supine position were as follows: systolic BP (SBP) decreased from 168.4 +/- 4.6 to 145.3 +/- 4.3 mm Hg (p less than 0.01); diastolic BP (DBP) decreased from 106.1 +/- 2.4 to 87.1 +/- 2.0 mm Hg (p less than 0.01); HR decreased from 77.9 +/- 1.6 to 63.2 +/- 1.7 b.p.m. (p less than 0.01); PRA decreased from 1.816 +/- 0.521 to 1.052 +/- 0.323 ng/ml/h (p less than 0.01). Creatinine clearance remained stable: 37.1 +/- 4.1 versus 37.1 +/- 4.7 ml/min/1.73 m2 (not significant). Similar results (for SBP, DBP, HR and PRA) were obtained in the erect position. It is concluded that tertatolol in hypertensive patients with CRF: significantly lowers BP and HR without excessive bradycardia, significantly lowers PRA, the most important decrease being observed for the highest initial PRA, does not alter renal function, and has a good clinical acceptability.

Adrenergic beta-Antagonists↗